1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2008. www.goldcopd.org/.
2. Zielinski J, MacNee W, Wedzicha J et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–7.
3. Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–15.
4. Eller J, Ede A, Schaberg T, Niederman MS et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
5. Puhan MA, Vollenweider D, Latshang T et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007; 8: 30.
6. Anthonisen NR, Manfreda J, Warren CPW et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
7. Nouira S, Marghli S, Belghith M et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbations requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020–5.
8. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
9. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.
10. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD. A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9–19.
11. Dev D, Sankaran EWR, Cunnife J et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir Med 1998; 92: 664–7.
12. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Урал. мед. журн. 2008; 13: 19–24.
13. Siempos II, Dimopoulos G, Korbila IP et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37.
14. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. антимикроб. химиотер. 2006; 8: 33–47.
15. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. арх. 2006; 78 (3): 25–35.
16. Cortvriendt WR, Verschoor JS, Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977–9.
17. Sourgens H, Steinbrede H, Verschoor JS et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet. Int J Clin Pharmacol Ther 2001; 39: 75–82.
18. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина/клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология. 2008; 2: 73–80.
19. El Moussaoui R, Roede BM, Speelman P et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415–22.
20. Roede BM, Bresser P, El Moussaoui R et al. Three vs. 10 days of amoxycillin–clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin Microbiol Infect 2007; 13: 284–90.